Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
about
Synthetic Peptides as Protein MimicsA strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinEvolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse modelApplying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine designA global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Phages and HIV-1: from display to interplay.A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody responseSynthesis of a trimeric gp120 epitope mimic conjugated to a T-helper peptide to improve antigenicityGenetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaquesMultiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignThe human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsNeutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.
P2860
Q26770255-6B0CF507-D129-451C-A074-122A68C9A4A0Q33522232-986B2DA2-50B9-465A-9E15-064C813FD1F2Q33676640-36665FFA-2793-42E7-909E-52BD147F5F95Q33743491-94EED063-E40E-404F-81C3-67CD78C12A9EQ33803590-B316B8F3-6CD0-4CC3-B909-66182234D77CQ34020606-DBA45DDF-9981-497B-B1B2-92D50111A755Q34225659-8D7091BB-A9CB-43BD-9C94-A98414A45779Q34273397-F28C8D35-11FF-4E80-A611-6499100CC621Q34357078-E3A86E80-CA49-4378-8611-82AFD0A6B7B3Q34709781-D46666CD-6512-4429-988E-E67B77243C3AQ34962907-A6406422-B742-44F7-A494-EC2FED76ECA9Q35105006-D5A5A906-F116-4EDB-A047-A02E8189B2ECQ36447540-15303348-5D4F-4E6B-8850-A190A64AA15CQ37099851-0A731627-6CD9-4028-BC5C-1C43BFCE5285Q38356290-B93CDE15-7366-4F4F-852E-A1EA5E57C3C5Q38695294-9D84DEE9-068C-4A5C-BEEC-4DC1D0AE6CFD
P2860
Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Anti-human immunodeficiency vi ...... age peptide display libraries.
@ast
Anti-human immunodeficiency vi ...... age peptide display libraries.
@en
type
label
Anti-human immunodeficiency vi ...... age peptide display libraries.
@ast
Anti-human immunodeficiency vi ...... age peptide display libraries.
@en
prefLabel
Anti-human immunodeficiency vi ...... age peptide display libraries.
@ast
Anti-human immunodeficiency vi ...... age peptide display libraries.
@en
P2093
P356
P1476
Anti-human immunodeficiency vi ...... age peptide display libraries.
@en
P2093
McKenna PM
Robinson JE
Zolla-Pazner S
P304
P356
10.1089/AID.1997.13.1549
P577
1997-12-01T00:00:00Z